Blood test may help personalize nerve disease treatment
NCT ID NCT04356781
First seen Feb 24, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This study examined 20 adults with chronic nerve conditions (CIDP or MMN) to see if changes in IgG levels after their first IVIg treatment could predict the long-term dose they need. Researchers aimed to find a faster, more precise way to adjust treatment, reducing side effects and costs. The study did not test a new therapy but gathered data to improve dosing strategies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Walton Centre NHS Foundation Trust
Liverpool, Merseyside, L9 7LJ, United Kingdom
Conditions
Explore the condition pages connected to this study.